Managing IP is part of the Delinian Group, Delinian Limited, 4 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 00954730
Copyright © Delinian Limited and its affiliated companies 2023

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

New Zealand: Australia and New Zealand are not always similar

A recent New Zealand High Court decision (Pharmazen Limited v Anagenix IP Limited [2019] NZHC 1520 (July 1 2019)) serves as a reminder of the subjective nature of the comparison of trademarks, with the court finding the marks “Actazin” and “ActiPhen” too similar, while on the same facts and evidence, an Australian hearings officer had decided the opposite.

What happened – a crisis of kiwifruit

The case involved the marks ­“Actazin” and “ActiPhen”, both covering kiwifruit powder. The applicant argued forcefully, but ultimately hopelessly, that the marks were to be applied to dissimilar goods. Unfortunately, neither the law nor common sense permitted this ­argument.

The applicant argued, perhaps surprisingly, that its goods, which included “kiwifruit powder (not for medical purposes) for use as an ingredient in dietary supplements” were not similar to the opponent’s goods, which included “kiwifruit extract powder as …an ingredient adapted for human health …use including dietary… supplements”. Its reasoning was that the actual goods sold by the parties were different due to their manufacturing procedures, additives, and water and enzyme activity. It further argued that there could be no likelihood of confusion because the opponent’s goods were not for sale in New Zealand.

The judge looked over the case law in this area, and reaffirmed that the comparison of goods in a specification is a purely notional exercise, and when considered on their face, the respective specifications were obviously similar, if not identical.

This meant the matter came down to a comparison of marks.

In each of the New Zealand and Australian decisions, the decision-maker was presented with a table breaking down the marks into their constituent parts, and was asked to analyse the similarities/differences between the marks in detail.

In the Australian decision, this review resulted in the marks being considered different aurally and visually.

In New Zealand, the hearings officer noted that the comparison is between the marks as a whole, having regard to their essential features; it is not a side-by-side comparison, and allowance must be made for imperfect recollection.

However, the hearings officer then made what might be considered a side-by-side comparison and held that the marks were similar because they both began with the prefix “act”, they had three syllables, and they ended with the letter “n”.

On appeal, the judge also noted the artificiality and inapplicability of such a side-by-side comparison, but still agreed with the hearings officer; the deciding factor being that the similarities occurred at the start of the marks. In so doing, the judge was mostly swayed by the similarity of the first syllable, opining that the first part of the mark is the most important because of the tendency of consumers to slur the second part.

The respective analyses at first instance and appeal both effectively applied an imperfect recollection test, but arguably such a test should not be applied without careful consideration of the likely customer. In neither case was there particular regard to the types of customers who would purchase the kiwifruit dietary supplements covered by the marks. Such health conscious customers of nutraceuticals are likely to be more sophisticated, and demonstrate a higher level of attention when making purchasing decisions. A lot was made of the aural similarities between the marks, whereas perhaps the visual comparison is more important because of the way the products are likely to be purchased off the shelf in a pharmacy, or online.

This case is somewhat of a departure from previous recent cases in New Zealand, which have taken a fairly robust approach along the lines of that seen in Australia, to the comparison of pharma or nutraceutical names, generally on the basis that relevant customers seem to be well versed in differentiating brands with common (often ingredient-based) prefixes.

In this case, the prefix “act” was chosen by both parties to indicate the active ­ingredient “Actinidin”, but because this was not yet commonplace on the register the descriptive nature of this prefix was not taken into account, leaving the first-comer Anagenix with a broader scope of protection than perhaps was warranted.

watts-victoria.jpg

Victoria Watts


Baldwins Intellectual PropertyLevel 15, HSBC House, 1 Queen St, Auckland 1010, New ZealandTel: +64 9 373 3137Fax: +64 9 373 2123email@baldwins.comwww.baldwins.com

more from across site and ros bottom lb

More from across our site

Civil society and industry representatives met in Geneva on Thursday, September 28 to discuss a potential expansion of the TRIPS waiver
Sources say the beta version of the USPTO’s new trademark search tool is a big improvement over the current system but that it isn’t perfect
Canadian counsel weigh in on the IP office’s decision to raise trademark filing fees in 2024 and how they’re preparing clients
We provide a rundown of Managing IP’s news and analysis coverage from the week, and review what’s been happening elsewhere in IP
Shira Perlmutter, US Register of Copyrights, discussed the Copyright Office's role in forming generative AI policy during a House of Representatives hearing
The award marks one of the highest-ever damages received by a foreign company in a trademark infringement suit in China
Two orders denying public access to documents have reignited a debate over a lack of transparency at the new court
Rouse’s new chief of operations and the firm’s CEO tell Managing IP why they think private equity backing will help it conquer Europe
Brian Landry, partner at Saul Ewing, reveals how applicants can prosecute patent applications in the wake of the Federal Circuit's In re Cellect ruling
Ronelle Geldenhuys of Australia’s Foundry IP considers the implications complex computer technologies such as AI have on decision-making